Greetings and welcome to the Kamada Ltd. Fourth Quarter and Fiscal Year 2020 Earnings Call. At this time all lines are in a listen-only mode. [Operator Instructions] As a reminder this conference is ...

Experienced Executive to Expand Opportunities for the Company's Protein Therapeutics Platform NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq:KMDA)(TASE:KMDA), a plasma-derived protein ...

Total Revenues-- $47 million in Q3, a 13% increase compared to the same period in 2024. Gross Profit and Margin-- $19.8 million with a margin of 42%, up from $17.2 million and 41% in Q3 2024.

Amir London, CEO of Kamada Pharmaceuticals, was recently a guest on Benzinga's All-Access. Kamada is a global biopharmaceutical company with a portfolio of assets indicated for rare and serious ...

Greetings and welcome to Kamada Ltd. second quarter 2019 earnings call. At this time, all participants are in a listen-only mode. A questions-and-answer session will follow the formal presentation.

Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript May 14, 2025 Kamada Ltd. reports earnings inline with expectations. Reported EPS is $0.07 EPS, expectations were $0.07. Operator: Greetings, ...

(RTTNews) - Kamada Ltd. (KMDA) has entered into agreements with two international pharmaceutical companies to commercialize three biosimilar product candidates in Israel. The three products are ...

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...

REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...